Consano Bio received FDA clearance of its investigational new drug application for C-1101, its lead therapy for chronic lumbosacral radiculopathy, commonly known as chronic sciatica. "People living with chronic lumbosacral radiculopathy have limited treatment options and often struggle to find lasting relief," Verrills said. Andrew Hall , chief executive officer of Consano Bio, framed the IND clearance as validation of the program's scientific and manufacturing rigor. "IND clearance confirms that C-1101 meets the high scientific and manufacturing standards required to begin clinical development in the United States. C-1101 is a potential first-in-class, disease-modifying, non-opioid modality that targets the root biology of chronic sciatica, a condition affecting millions with no FDA-approved pharmaceutical treatment."